Microarray hybridization for assessment of the genetic stability of chimeric west nile/dengue 4 virus

Journal of Medical Virology

Volumn 83, Issue 5, 2011, Pages 910-920

  Laassri, Majid ^a,c   Bidzhieva, Bella ^a,c   Speicher, James ^b   Pletnev, Alexander G ^b   Chumakov, Konstantin ^a,c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Flavivirus vaccine; Molecular consistency; Mutants quantitation; Mutants screening; Quality control

Indexed keywords

AMINO ACID; LIVE VACCINE; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5; OLIGONUCLEOTIDE; VIRUS ENVELOPE PROTEIN; WEST NILE VACCINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS 4; EMBRYO; ENCEPHALITIS; ENVELOPE GENE; FEMALE; GENETIC SCREENING; GENETIC STABILITY; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MICROARRAY ANALYSIS; MOLECULAR HYBRIDIZATION; MOUSE; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGONUCLEOTIDE PROBE; POINT MUTATION; QUALITY CONTROL; VACCINATION; VERO CELL; VIROGENESIS; VIRUS GENE; VIRUS MUTANT; VIRUS VIRULENCE; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

ANIMALS; CELL LINE; DENGUE VIRUS; DNA PRIMERS; GENOMIC INSTABILITY; HUMANS; MICROARRAY ANALYSIS; NUCLEIC ACID HYBRIDIZATION; POINT MUTATION; RECOMBINATION, GENETIC; SERIAL PASSAGE; VIROLOGY; VIRUS CULTIVATION; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

FLAVIVIRUS; MUS; WEST NILE VIRUS;

EID: 79952731679     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22033     Document Type: Article

References (32)

1. Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX. 2001. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 75: 4268-4275.
2. Blaney JE, Jr., Johnson DH, Manipon GG, Firestone CY, Hanson CT, Murphy BR, Whitehead SS. 2002. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300: 125-139.
3. Burke DC, Monath TP. 2001. Fields virology. In: Knipe DM, Howley PM, editors. Flaviviruses. Philadelphia: Williams and Wilkins. pp. 1043-11251.
4. Cherkasova E, Laassri M, Chizhikov V, Korotkova E, Dragunsky E, Agol VI, Chumakov K. 2003. Microarray analysis of evolution of RNA viruses: Evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc Natl Acad Sci USA 100: 9398-9403.
5. Chumakov KM, Powers LB, Noonan KE, Roninson IB, Levenbook IS. 1991. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci USA 88: 199-203.
6. Chumakov KM, Norwood LP, Parker ML, Dragunsky EM, Ran YX, Levenbook IS. 1992. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J Virol 66: 966-970.
7. Diamond MS. 2009. Mechanisms of evasion of the type I interferon antiviral response by flaviviruses. J Interferon Cytokine Res 29: 521-530.
8. Dunster LM, Wang H, Ryman KD, Miller BR, Watowich SJ, Minor PD, Barrett AD. 1999. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology 261: 309-318.
9. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405-413.
10. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T. 2004. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78: 4761-4775.
11. Laassri M, Dragunsky E, Enterline J, Eremeeva T, Ivanova O, Lottenbach K, Belshe R, Chumakov K. 2005. Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization. J Clin Microbiol 43: 2886-2894.
12. Laassri M, Meseda CA, Williams O, Merchlinsky M, Weir JP, Chumakov K. 2007. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene. J Med Virol 79: 791-802.
13. Lindenbach BD, Rice CM. 2003. Molecular biology of flaviviruses. Adv Virus Res 59: 23-61.
14. Lindenbach B, Thiel H, Rice C. 2007. Flaviviridae: The viruses and their replication. In: Knipe D, Howley P, editors. Fields virology, 5th edition. Philadelphia: Lippincott-Raven Publishers. pp. 1101-1152.
15. Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett AD, Shope RE, Ratterree M, Chambers TJ, Guirakhoo F. 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17: 1869-1882.
16. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH. 2006. Crystal structure of the West Nile virus envelope glycoprotein. J Virol 80: 11467-11474.
17. Petersen LR, Hayes EB. 2008. West Nile Virus in the Americas. Med Clin North Am 92: 1307-1322.
18. Pletnev AG, Men R. 1998. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. Proc Natl Acad Sci USA 95: 1746-1751.
19. Pletnev AG, Bray M, Huggins J, Lai CJ. 1992. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc Natl Acad Sci USA 89: 10532-10536.
20. Pletnev AG, Karganova GG, Dzhivanyan TI, Lashkevich VA, Bray M. 2000. Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus. Virology 274: 26-31.
21. Pletnev AG, Bray M, Hanley KA, Speicher J, Elkins R. 2001. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: Evaluation in rhesus monkeys and in mosquitoes. J Virol 75: 8259-8267.
22. Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW. 2002. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci USA 99: 3036-3041.
23. Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM. 2003. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 314: 190-195.
24. Pletnev AG, Swayne DE, Speicher J, Rumyantsev AA, Murphy BR. 2006. Chimeric West Nile/dengue virus vaccine candidate: Preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 24: 6392-6404.
25. Pugachev KV, Ocran SW, Guirakhoo F, Furby D, Monath TP. 2002. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine 20: 996-999.
26. Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, Girakhoo S, Pougatcheva SO, Arroyo J, Trent DW, Monath TP. 2004. High fidelity of yellow fever virus RNA polymerase. J Virol 78: 1032-1038.
27. Pugachev KV, Schwaiger J, Brown N, Zhang ZX, Catalan J, Mitchell FS, Ocran SW, Rumyantsev AA, Khromykh AA, Monath TP, Guirakhoo F. 2007. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE). Vaccine 25: 6661-6671.
28. Reed SC. 1938. Uniovular twins in mice. Science 88: 13.
29. Robertson SJ, Mitzel DN, Taylor RT, Best SM, Bloom ME. 2009. Tick-borne flaviviruses: Dissecting host immune responses and virus countermeasures. Immunol Res 43: 172-186.
30. Wade MM, Volokhov D, Peredelchuk M, Chizhikov V, Zhang Y. 2004. Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn Microbiol Infect Dis 49: 89-97.
31. WHO O. 2002. Recommendations for the production and control of poliomyelitis vaccine (oral). Geneva, Switzerland: WHO.
32. Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, Mukhopadhyay S, Baker TS, Strauss JH, Rossmann MG, Kuhn RJ. 2003. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 10: 907-912.